Search

Your search keyword '"UNICANCER"' showing total 7,478 results
Start Over Author "UNICANCER"
7,478 results on '"UNICANCER"'

2. Validation of the European Oncology Quality of Life Toolkit

Author

Gustave Roussy, Cancer Campus, Grand Paris, German Cancer Research Center, Oslo universitetssykehus HF, The Netherlands Cancer Institute, Hospital del Mar Research Institute, Istituto Europeo di Oncologia, European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER, EAPC, Institut Curie, EUROPEAN CANCER ORGANISATION, DIGICORE/IFO, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Alleanza Contro il Cancro, Istituti Fisioterapici Ospitalieri, STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG, University of Milan, SporeData OÜ, ORGANISATION OF EUROPEAN CANCER INSTITUTES, FEDERAZIONE ITALIANA DELLE ASSOCIAZIONI DI VOLONTARIATO IN ONCOLOGIA, Medical University Innsbruck, SDRUZHENIE ASOTSIATSIA NA PATSIENTITE SONKOLOGICHNI ZABOLYAVANIA I PRIYATELI, FEDERATIA ASOCIATIILOR BOLNAVILOR DE CANCER, University of Leeds, The Leeds Teaching Hospitals NHS Trust, and Region Hovedstaden (Bispebjerg Hospital & Rigshospitalet)

Published
2024

16. Implementation, Effectiveness and Impact of a Value Based Intervention for Patients With Breast or Lung Cancer (VOICE)

Author

Hospital de Cruces, Hospital Donostia, Hospital Universitario 12 de Octubre, Complejo Hospitalario de Especialidades Juan Ramón Jimenez, Institut Català d'Oncologia, Hospital Universitari de Bellvitge, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Instituto Portugues de Oncologia, Francisco Gentil, Porto, Onze Lieve Vrouwziekenhuis Aalst, and UNICANCER

Published
2024

24. Prospective Cohort of Patients With Hepatocellular Carcinoma in France (CHIEF)

Author

Biobanque de Picardie, Société Nationale Française de Gastroentérologie, Association Française pour l'Etude du Foie (AFEF), Federation Francophone de Cancerologie Digestive, Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux (ANGH), UNICANCER, Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR), Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie (CREGG), Association de Chirurgie Hépato-Bilio-Pancréatique et de Transplantation (ACHBT), Société Française de Pathologie (SFP), Société Française de Radiologie (SFR), and Societe Francaise de Radiotherapie Oncologique

Published
2023

43. Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Author

Thomas, Fabienne, Launay, Manon, Guitton, Jérôme, Loriot, Marie-Anne, Boyer, Jean-Christophe, Haufroid, Vincent, Etienne-Grimaldi, Marie-Christine, Royer, Bernard, GPCO-UNICANCER Group, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, and UCL - (SLuc) Service de biochimie médicale

Subjects
Pharmacology, Dihydropyrimidine Dehydrogenase Deficiency, Humans, Pharmacology (medical), Fluorouracil, Uracil, Dihydrouracil Dehydrogenase (NADP)
Abstract

To the Editor: We read with interest the article by de With et al. reporting the results of a prospective multicenter study where pretreatment uracil blood samples were collected and handled in 17 Dutch hospitals but analyzed in the reference hospital. [...]

Published
2022

44. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre de génétique médicale UCL, Delaloge, Suzette, Dureau, Sylvain, D'Hondt, Véronique, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, Francois P, Levy, Christelle, Lerebours, Florence, Mouret-Reynier, Marie A, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Callens, Cécile, Gentien, David, Rapinat, Audrey, Manduzio, Helene, Vincent-Salomon, Anne, Lemonnier, Jérôme, Cottu, Paul, French Breast cancer Intergroup Unicancer-UCBG, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre de génétique médicale UCL, Delaloge, Suzette, Dureau, Sylvain, D'Hondt, Véronique, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, Francois P, Levy, Christelle, Lerebours, Florence, Mouret-Reynier, Marie A, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Callens, Cécile, Gentien, David, Rapinat, Audrey, Manduzio, Helene, Vincent-Salomon, Anne, Lemonnier, Jérôme, Cottu, Paul, and French Breast cancer Intergroup Unicancer-UCBG

Abstract

Besides their development as additional adjuvant treatments, CDK4/6 inhibitors combined with endocrine therapy could represent less toxic alternatives to chemotherapy in postmenopausal women with high-risk oestrogen receptor-positive, HER2-negative breast cancer currently a candidate for chemotherapy. The multicentre, international, randomised phase 2 NEOPAL trial showed that the letrozole-palbociclib combination led to clinical and pathological responses equivalent to sequential anthracycline-taxanes chemotherapy. Secondary objectives included survival outcomes. Secondary end-points of NEOPAL included progression-free survival (PFS) and invasive-disease free survival (iDFS) in the intent-to-treat population. Exploratory end-points were overall survival (OS) and breast cancer specific survival (BCSS) in the intent-to-treat population, as well as iDFS, OS and BCSS according to the administration of chemotherapy. Hundred and six patients were randomised. Pathological complete response rates were 3.8% and 5.9%. Twenty-three of the 53 patients in the letrozole-palbociclib arm received postoperative adjuvant chemotherapy. At a median follow-up of 40.4 months [0-56.6], 11 progressions have been observed, of which three were in the letrozole-palbociclib and 8 in the control arm. PFS (HR = 1.01; [95%CI 0.36-2.90], p = 0.98) and iDFS (HR = 0.83; [95%CI 0.31-2.23], p = 0.71) did not differ between both arms. The 40 months PFS rate was 86.7% [95%CI 78.0-96.4] and 89.9% [95%CI 81.8-98.7] in letrozole-palbociclib and control arms, respectively. Outcomes of patients who did not receive chemotherapy were not statistically different from those who received it. NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes. Larger confirmatory studies are needed.

Published
2022

45. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

Author

Delaloge, Suzette, Dureau, Sylvain, D'Hondt, Véronique, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, François, Levy, Christelle, Lerebours, Florence, Mouret-Reynier, Marie A, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Callens, Cécile, Gentien, David, Rapinat, Audrey, Manduzio, Helene, Vincent-Salomon, Anne, Lemonnier, Jérôme, Cottu, Paul, French Breast cancer Intergroup Unicancer-UCBG, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)

Subjects
Cancer Research, Survival, Pyridines, Receptor, ErbB-2, [SDV]Life Sciences [q-bio], Breast Neoplasms, Survival Analysis, Neoadjuvant Therapy, Piperazines, CDK4/6 inhibitor, Oncology, Receptors, Estrogen, Luminal breast cancer, Antineoplastic Combined Chemotherapy Protocols, Letrozole, Humans, Chemotherapy, Female, Neoadjuvant
Abstract

Besides their development as additional adjuvant treatments, CDK4/6 inhibitors combined with endocrine therapy could represent less toxic alternatives to chemotherapy in postmenopausal women with high-risk oestrogen receptor-positive, HER2-negative breast cancer currently a candidate for chemotherapy. The multicentre, international, randomised phase 2 NEOPAL trial showed that the letrozole-palbociclib combination led to clinical and pathological responses equivalent to sequential anthracycline-taxanes chemotherapy. Secondary objectives included survival outcomes. Secondary end-points of NEOPAL included progression-free survival (PFS) and invasive-disease free survival (iDFS) in the intent-to-treat population. Exploratory end-points were overall survival (OS) and breast cancer specific survival (BCSS) in the intent-to-treat population, as well as iDFS, OS and BCSS according to the administration of chemotherapy. Hundred and six patients were randomised. Pathological complete response rates were 3.8% and 5.9%. Twenty-three of the 53 patients in the letrozole-palbociclib arm received postoperative adjuvant chemotherapy. At a median follow-up of 40.4 months [0-56.6], 11 progressions have been observed, of which three were in the letrozole-palbociclib and 8 in the control arm. PFS (HR = 1.01; [95%CI 0.36-2.90], p = 0.98) and iDFS (HR = 0.83; [95%CI 0.31-2.23], p = 0.71) did not differ between both arms. The 40 months PFS rate was 86.7% [95%CI 78.0-96.4] and 89.9% [95%CI 81.8-98.7] in letrozole-palbociclib and control arms, respectively. Outcomes of patients who did not receive chemotherapy were not statistically different from those who received it. NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes. Larger confirmatory studies are needed.

Published
2022

46. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Author

Conroy, Thierry, Hammel, Pascal, Hebbar, Mohamed, Ben Abdelghani, Meher, Wei, Alice, Raoul, Jean-Luc, Choné, Laurence, Francois, Eric, Artru, Pascal, Biagi, James, Lecomte, Thierry, Assenat, Eric, Faroux, Roger, Ychou, Marc, Volet, Julien, Sauvanet, Alain, Breysacher, Gilles, Di Fiore, Frédéric, Cripps, Christine, Kavan, Petr, Texereau, Patrick, Bouhier-Leporrier, Karine, Khemissa-Akouz, Faiza, Legoux, Jean-Louis, Juzyna, Beata, Gourgou, Sophie, O'Callaghan, Christopher, Jouffroy-Zeller, Claire, Rat, Patrick, Malka, David, Castan, Florence, Bachet, Jean-Baptiste, Trials Group, Canadian Cancer, Group, Unicancer-GI–PRODIGE, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, CRLCC Paul Strauss, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Hôpital privé Jean Mermoz, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de chirurgie hepato-pancreato-biliaire, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Louis Pasteur [Colmar] (CH Colmar), CHU Rouen, Normandie Université (NU), CHU Mont de Marsan, Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Saint Jean de Perpignan, Centre Hospitalier Régional d'Orléans (CHRO), R&D UNICANCER, Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCL/UNICANCER), UNICANCER-UNICANCER, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Oncologie digestive, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Service d'Hépato-Gastro-Entérologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CRLCC Antoine Lacassagne, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Centre Hospitalier Régional d'Orléans (CHR), Service de Gastroentérologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Adult, Male, medicine.medical_specialty, FOLFIRINOX, Leucovorin, [SDV.CAN]Life Sciences [q-bio]/Cancer, Irinotecan, Deoxycytidine, Gastroenterology, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Pancreatic cancer, Antineoplastic Combined Chemotherapy Protocols, Organometallic Compounds, medicine, Adjuvant therapy, Humans, Prospective Studies, Survival rate, Aged, Proportional Hazards Models, Aged, 80 and over, business.industry, Combination chemotherapy, General Medicine, Middle Aged, medicine.disease, Gemcitabine, 3. Good health, Oxaliplatin, Pancreatic Neoplasms, Drug Combinations, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Fluorouracil, Folfirinox Regimen, Lung Diseases, Interstitial, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, medicine.drug
Abstract

International audience; BACKGROUND:Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer.METHODS:We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety.RESULTS:At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P

Published
2018

47. Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation.

Author

UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Centre de toxicologie clinique, UCL - (SLuc) Centre de génétique médicale UCL, Thomas, F, Maillard, M, Launay, M, Tron, C, Etienne-Grimaldi, M-C, Gautier-Veyret, E, Haufroid, V, Pallet, N, Royer, B, Narjoz, C, Schmitt, A, Groupe de Pharmacologie Clinique Oncologique (GPCO-UNICANCER), UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Centre de toxicologie clinique, UCL - (SLuc) Centre de génétique médicale UCL, Thomas, F, Maillard, M, Launay, M, Tron, C, Etienne-Grimaldi, M-C, Gautier-Veyret, E, Haufroid, V, Pallet, N, Royer, B, Narjoz, C, Schmitt, A, and Groupe de Pharmacologie Clinique Oncologique (GPCO-UNICANCER)

Abstract

No abstract available

Published
2021

48. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Author

Jaafar Bennouna, Yves Becouarn, C. Lepere, for Prodige investigators, Gercor, Fédération Française de Cancérologie Digestive, Laurent Mineur, Gaël Deplanque, Aimery de Gramont, Louis Marie Dourthe, Ahmed Khalil, Joëlle Egreteau, Marine Hug de Larauze, Unicancer, Jean-Baptiste Bachet, Roger Faroux, Jérôme Desramé, Olivier Dupuis, S. Fratte, Jeremie Bez, Thierry André, Marc Ychou, François Ghiringhelli, Olivier Bouché, May Mabro, Julien Taieb, Dewi Vernerey, Marie Pierre Galais, Christophe Louvet, Jérôme Dauba, Sophie Paget-Bailly, Franck Bonnetain, Benoist Chibaudel, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut Sainte Catherine [Avignon], Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Hôpital privé Jean Mermoz, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, CH Belfort-Montbéliard, Fédération Francophone de la Cancérologie Digestive, FFCD, Centre Hospitalier Layné, Institut Mutualiste de Montsouris (IMM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Clinique Victor Hugo, Institut Bergonié [Bordeaux], Hôpital Foch [Suresnes], Groupe Hospitalier Bretagne Sud (GHBS), Hôpital universitaire Robert Debré [Reims], Groupe Hospitalier Paris Saint-Joseph, Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), Clinique Sainte Anne [Strasbourg], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Tenon [AP-HP], Institut hospitalier Franco-Britannique [Levallois-Perret], Université Sorbonne Paris Cité (USPC), Université Paris Descartes - Paris 5 (UPD5), CHU Saint-Antoine [APHP], Groupe cooperateur multidisciplinaire en oncologie (GERCOR), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Inserm UMR 1098, Centre René Gauducheau - ICO, institut de Cancerologie de l'Ouest, Institut de cancérologie de l'Ouest - Paul Papin (ICO - Paul Papin), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut Bergonié - CRLCC Bordeaux, centre hospitalier Bretagne sud, Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), CHU Pitié-Salpêtrière [APHP], and CHU Tenon [APHP]

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Clinical endpoint, medicine, education, education.field_of_study, Chemotherapy, business.industry, medicine.disease, 3. Good health, Oxaliplatin, 030104 developmental biology, Oncology, Fluorouracil, 030220 oncology & carcinogenesis, business, Adjuvant, medicine.drug
Abstract

Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages to patients and health care providers. Methods In International Duration Evaluation of Adjuvant Chemotherapy (IDEA) France, as part of the IDEA international collaboration, patient with colon cancer patients were randomly assigned to 3 and 6 months of modified FOLFOX6 (mFOLFOX6: infusional fluorouracil, leucovorin, and oxaliplatin) or capecitabine plus oxaliplatin (CAPOX) by physician choice. The primary end point was disease-free survival (DFS), and analyses were descriptive. Results A total of 2,010 eligible patients received either 3 or 6 months of chemotherapy (modified intention-to-treat population); 2,000 (99%) had stage III colon cancer (N1: 75%, N2: 25%); 1,809 (90%) received mFOLFOX6, and 201 (10%) received CAPOX. The median age was 64 years, and the median follow-up time was 4.3 years. Overall, 94% (3 months) and 78% (6 months) of patients completed treatment (fluoropyrimidines ± oxaliplatin). Maximal grade 2 and 3 neuropathy rates were 28% and 8% in the 3-month arm and 41% and 25% in the 6-month arm ( P < .001). Final rates of residual neuropathy greater than grade 1 were 3% in the 3-month arm and 7% in the 6-month arm ( P < .001). There were 578 DFS events: 314 and 264 in the 3- and 6-month arms, respectively. The 3-year DFS rates were 72% and 76% in the 3- and 6-month arms, respectively (hazard ratio [HR], 1.24; 95% CI, 1.05 to 1.46; P = .0112). In the 3 and 6-month arms, respectively, for patients who received mFOLFOX6, the 3-year DFS rates were 72% and 76% (HR, 1.27; 95% CI, 1.07 to 1.51); for the T4 and/or N2 population, they were 58% and 66% (HR, 1.44; 95% CI, 1.14 to 1.82); and for the T1-3N1 population, they were 81% and 83% (HR, 1.15; 95% CI, 0.89 to 1.49). Conclusion IDEA France, in which 90% of patients received mFOLFOX6, shows superiority of 6 months of adjuvant chemotherapy compared with 3 months, especially in the T4 and/or N2 subgroups. These results should be considered alongside the international IDEA collaboration data.

Published
2018

49. Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

Author

Joël Guigay, Anne Aupérin, Jerome Fayette, Esma Saada-Bouzid, Cédrik Lafond, Miren Taberna, Lionnel Geoffrois, Laurent Martin, Olivier Capitain, Didier Cupissol, Hélène Castanie, Damien Vansteene, Philippe Schafhausen, Alison Johnson, Caroline Even, Christian Sire, Sophie Duplomb, Camille Evrard, Jean-Pierre Delord, Brigitte Laguerre, Sylvie Zanetta, Cécile Chevassus, Aldéric Fraslin, Fanny Louat, Laura Sinigaglia, Ulrich Keilholz, Jean Bourhis, Ricard Mesia, and GORTEC, AIO, TTCC, UniCancer H& Group

Subjects
medicine.medical_specialty, Performance status, Cetuximab, business.industry, Head and neck cancer, medicine.disease, law.invention, Regimen, Randomized controlled trial, Quality of life, law, Internal medicine, medicine, Clinical endpoint, Adverse effect, business, medicine.drug
Abstract

Background: After promising results from TPEx phase II trial in first line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), this trial compared the TPEx regimen (docetaxel-platinum-cetuximab) to the standard EXTREME regimen. Methods: Patients with R/M HNSCC unsuitable for curative treatment were randomized between TPEx (four cycles docetaxel-cisplatin-cetuximab followed by cetuximab maintenance 500 mg/m² every two weeks) and EXTREME (six cycles 5FU-cisplatin-cetuximab followed by weekly cetuximab 250 mg/m² maintenance). Main inclusion criteria were patients fit for cisplatin, performance status (PS) ≤1, creatinine clearance >60ml/min, and age

Published
2020

50. Recommandations françaises du Groupe Génétique et Cancer pour l’analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l’ovaire

Author

Christine Lasset, Olivier Caron, Pascal Pujol, Jessica Moretta, Nadine Andrieu, Pascaline Berthet, Véronica Cusin, Michel Longy, Dominique Vaur, Christophe Jamain, Odile Cohen-Haguenauer, Antoine De Pauw, Elisabeth Luporsi, Christine Maugard, Chrystelle Colas, Catherine Noguès, Sophie Dussart, Groupe Génétique et Cancer d’Unicancer, Tan Dat Nguyen, Carole Corsini, Valérie Bonadona, and Capucine Delnatte

Subjects
0301 basic medicine, 03 medical and health sciences, Cancer Research, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Radiology, Nuclear Medicine and imaging, Hematology, General Medicine, 3. Good health
Abstract

Resume Introduction Dans le contexte d’une suspicion de predisposition aux cancers du sein et de l’ovaire, le sequencage haut debit permet desormais d’analyser de nombreux genes simultanement. Ainsi, de nouveaux « panels de genes sein/ovaire » ont ete developpes en France, avec une grande diversite dans leur composition, ainsi que dans la prise en charge medicale des personnes porteuses de mutations, faute de referentiels. Une homogeneisation des pratiques est indispensable. Methodes Le Groupe Genetique et Cancer (GGC) – Unicancer a conduit un travail exhaustif bibliographique sur 18 genes d’interet, et retenu les publications avec des estimations de risque de cancer non biaisees. Resultats Cette expertise a permis de definir un panel de 13 genes identifies d’utilite clinique : risque relatif de cancer superieur a 4, possibilites de prise en charge medicale et de tests genetiques presymptomatiques dans les familles. Ainsi devant toute suspicion de predisposition aux cancers du sein et de l’ovaire, le GGC recommande l’analyse de BRCA1, BRCA2, PALB2, TP53, CDH1, PTEN, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2, EPCAM. Les raisons pour ne pas inclure les genes NBN, RAD51B, CHEK2, STK11, ATM, BARD1, BRIP1 sont presentees. Les preconisations de depistage, de prevention et de conseil genetique associees a tous les genes expertises sont revues. Discussion Les connaissances evoluant rapidement, une mise a jour annuelle de la bibliographie est prevue par le GGC pour faire evoluer le panel, et des etudes d’epidemiologie genetique se mettent en place afin d’estimer plus precisement les risques de cancers associes aux genes non retenus.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results